by Maria Zannes | Aug 18, 2025 | Press Releases
Financial and Clinical Leaders Provide Significant Expertise for the Company’s Commercial Growth SAN ANTONIO, Texas (August 18, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company advancing noninvasive diagnostics for the early...
by Maria Zannes | Aug 14, 2025 | Press Releases
SAN ANTONIO, Texas (August 14, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced the closing of its previously announced private...
by Maria Zannes | Aug 14, 2025 | Press Releases
CyPath® Lung revenues up 62% year-over-year in first six months of 2025 SAN ANTONIO, Texas (August 14, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on providing noninvasive, accurate detection of early-stage lung...
by Maria Zannes | Aug 13, 2025 | Press Releases
SAN ANTONIO, Texas (August 13, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into securities purchase...
by Maria Zannes | Aug 13, 2025 | Press Releases
July Test Volume Surges 72% Over Prior Monthly Average SAN ANTONIO, TX – August 13, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge...
by Maria Zannes | Jul 29, 2025 | Press Releases
bioAffinity Technologies’ noninvasive sputum test catches rare cancer in time for curative surgery SAN ANTONIO, TX – July 29, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer...
